Abbott reports positive FreeDM2 study results for CGM

Abbott has announced results from the FreeDM2 randomised controlled trial (RCT), indicating that improved glucose outcomes were observed in individuals using the FreeStyle Libre c ...
Drug Delivery Business

Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin

Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).

What you should know about wearable glucose monitors in wake of recall

About 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors manufactured by Abbott were recalled in November, because they might give wrong readings.